Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small cell lung cancer (NSCLC). Response and survival rates in advanced stage NSCLC, unlike other cancers, rely on response to first-line therapy. Immunotherapy with PD(L)1-based therapy, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. While immunotherapy has improved survival rate, the prognosis remains poor with most patients receiving chemotherapy after immunotherapy. Many types of tumors tend to lose cells or release different types of cellular products including their deoxyribonucleic acid (DNA) which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. The first part of this trial, studying samples of blood and tissue in the laboratory from patients receiving immunotherapy may help doctors learn more about the effects PD(L)1-based therapy on cells. It may also help doctors understand how well patients respond to treatment and may help develop new individualized treatment strategies. The second part of this trial also tests the effect of second-line immunotherapy, such as tremelimumab and durvalumab or adagrasib and bevacizumab, in treating patients with NSCLC with specific genetic mutations that is growing, spreading or getting worse (progressive). Tremelimumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adagrasib, a type of targeted therapy, may stop the growth of tumor cells by blocking a protein needed for tumor cell growth and may kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving second-line immunotherapy, tremelimumab and durvalumab or adagrasib with bevacizumab, may be safe, tolerable, and/or effective in treating patients with stage IIIB/IV NSCLC with specific genetic mutations.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony zaawansowany rak płuca (stadium IIIB lub IV)
- •Wyniki testów genetycznych wykonane w ciągu ostatnich 3 miesięcy lub dostępna próbka tkanki do zbadania
- •Zgoda na pobieranie próbek krwi do badań
- •Planowane rozpoczęcie leczenia immunoterapią zatwierdzoną przez FDA
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG ≤ 2)
- •Mierzalne ogniska nowotworu widoczne w badaniach
- •Wyniki badań krwi w normie (liczba białych krwinek, płytek krwi, hemoglobina, funkcja wątroby)
✗ Disqualifies
- •Brak szczegółowych kryteriów wykluczenia podanych w dostępnym tekście
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
CTCA at Western Regional Medical Center
Goodyear, United States
City of Hope Corona
Corona, United States
City of Hope Medical Center
Duarte, United States
City of Hope Seacliff
Huntington Beach, United States
City of Hope at Irvine Lennar
Irvine, United States
City of Hope Antelope Valley
Lancaster, United States
City of Hope at Long Beach Elm
Long Beach, United States
City of Hope at Newport Beach Fashion Island
Newport Beach, United States
City of Hope South Pasadena
South Pasadena, United States
City of Hope South Bay
Torrance, United States
City of Hope Upland
Upland, United States
City of Hope Atlanta Cancer Center
Newnan, United States
City of Hope at Chicago
Zion, United States
Trial contact
Ravi Salgia
Ravi Salgia
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.